Can underpowered clinical trials be justified?

IRB Ethics and Human Research

Volumn 26, Issue 3, 2004, Pages 16-19

  Rosoff, Philip M ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; AUTOTRANSPLANTATION; BIOMEDICAL AND BEHAVIORAL RESEARCH; BREAST TUMOR; CLINICAL TRIAL; EQUIPMENT; ETHICS; FEMALE; HUMAN; METHODOLOGY; PROFESSIONAL STANDARD; RESEARCH SUBJECT; STANDARD; STEM CELL TRANSPLANTATION;

BIOMEDICAL AND BEHAVIORAL RESEARCH;

BREAST NEOPLASMS; CLINICAL TRIALS; EFFECT MODIFIERS (EPIDEMIOLOGY); ETHICAL REVIEW; ETHICS COMMITTEES, RESEARCH; FEMALE; HUMANS; RESEARCH DESIGN; RESEARCH SUBJECTS; STEM CELL TRANSPLANTATION; TRANSPLANTATION, AUTOLOGOUS;

EID: 6044221088     PISSN: 01937758     EISSN: None     Source Type: Journal    
DOI: 10.2307/3563753     Document Type: Review

References (37)

1. Emanuel EJ, Wendler D, Grady C. What makes clinical research ethical? JAMA 2000;283:2701-2711;
2. Weinberg JM, Kleinman KP, Good study design and analysis plans as features of ethical research with humans. IRB: Ethics & Human Research 2003;25(5):11-14.
3. See ref. 1, Weinberg and Kleinman 2003.
4. See ref. 1, Emanuel et al. 2000.
5. 45 CFR 46. Protection of Human Research Subjects.
6. Parts I and II: policies and guidelines relating to the cancer-center support grant. (September, 2003) http://www3.cancer.gov/cancer-centers/download/ ccsg.pdf, Accessed on January 12, 2004.
7. Halpern SD, Karlawish JH, Berlin JA. The continuing unethical conduct of underpowered clinical trials. JAMA 2002;288:358-362.
8. Edwards SJ, Braunholtz DA. Can unequal be more fair? A response to Andrew Avins. Journal of Medical Ethics 2000;26:179-182.
9. See ref. 1, Emanuel et al. 2000; Minogue BP, Palmer-Fernandez G, Udell L, et al. Individual autonomy and the double-blind controlled experiment: The case of desperate volunteers. Journal of Medical Philosophy 1995;20:43-55.
10. Lilford RJ, Thornton JG, Braunholtz D. Clinical trials and rare diseases: A way out of a conundrum. BMJ 1995;311:1621-1625.
11. See ref. 9, Lilford et al. 1995; Kadane JB, eds. Bayesian Methods and Ethics in a Clinical Trial Design. New York: John Wiley & Sons, 1996.
12. Sollitto S, Hoffman S, Mehlman M, et al. Intrinsic conflicts of interest in clinical research: A need for disclosure. Kennedy Institute of Ethics Journal 2003;13:83-91;
13. Morin K, Rakatansky H, Riddick FA, Jr., et al. Managing conflicts of interest in the conduct of clinical trials. JAMA 2002;287:78-84.
14. 45 CFR 46.101(b).
15. Roethlisberger FH, Dickson WJ. Management and the Worker. Cambridge, MA: Harvard University Press, 1939.
16. Braunholtz DA, Edwards SJ, Lilford RJ. Are randomized clinical trials good for us (in the short term)? Evidence for a "trial effect." Journal of Clinical Epidemiology 2001;54:217-224;
17. De Amici D, Klersy C, Ramajoli F, et al. Impact of the Hawthorne effect in a longitudinal clinical study: The case of anesthesia. Controlled Clinical Trials 2000;21:103-114.
18. Gruber T, Sharma A, Daneschvar H, et al. The Hawthorne effect in the assessment of pain by house staff. American Journal of Hospital Palliative Care 2003;20:231-234;
19. Lantos JD. The "inclusion benefit" in clinical trials. Journal of Pediatrics 1999;134:130-131;
20. Leung WC, Lam HS, Lam KW, et al. Unexpected reduction in the incidence of birth trauma and birth asphyxia related to instrumental deliveries during the study period: Was this the Hawthorne effect? British Journal of Gynecology 2003;110:319-322;
21. Rheineck-Leyssius AT, Kalkman CJ, Trouwborst A. Influence of motivation of care providers on the incidence of postoperative hypoxaemia in the recovery room. British Journal of Anaesthesiology 1996;77:453-457.
22. Antman KH, Rowlings PA, Vaughan WP, et al. High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America. Journal of Clinical Oncology 1997;15:1870-1879;
23. Baynes RD, Dansey RD, Klein JL, et al. High-dose chemotherapy and hematopoietic stem cell transplantation for breast cancer: Past or future? Seminars in Oncology 2001;28:377-388;
24. Dicato M. High-dose chemotherapy in breast cancer: Where are we now? Seminars in Oncology 2002;29:16-20;
25. Elfenbein GJ. Stem-cell transplantation for high-risk breast cancer. NEJM 2003;349:80-82;
26. Farquhar C, Basser R, Marjoribanks J, et al. High dose chemotherapy and autologous bone marrow or stem cell transplantation versus conventional chemotherapy for women with early poor prognosis breast cancer. Cochrane Database Systems Review 2003; CD003139;
27. Mello MM, Brennan TA. The controversy over high-dose chemotherapy with autologous bone marrow transplant for breast cancer. Health Affairs 2001;20:101-117;
28. Roche H, Viens P, Biron P, et al. High-dose chemotherapy for breast cancer: The French PEGASE experience. Cancer Control 2003;10:42-47;
29. Rodenhuis S, Bontenbal M, Beex LV, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer. NEJM 2003;349:7-16;
30. Schrama JG, Faneyte IF, Schornagel JH, et al. Randomized trial of high-dose chemotherapy and hematopoietic progenitor-cell support in operable breast cancer with extensive lymph node involvement: Final analysis with 7 years of follow-up. Annals of Oncology 2002;13:689-698;
31. Stadtmauer EA, O'Neill A, Goldstein LJ, et al. Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. Philadelphia Bone Marrow Transplant Group. NEJM 2000;342:1069-1076;
32. Stephenson J. Researchers struggle with trials of stem-cell transplants for breast cancer. JAMA 1997;277:1827-1829;
33. Weiss RB, Rifkin RM, Stewart FM, et al. High-dose chemotherapy for high-risk primary breast cancer: An on-site review of the Bezwoda study. Lancet 2000;355:999-1003;
34. Welch HG, Mogielnicki J. Presumed benefit: Lessons from the American experience with marrow transplantation for breast cancer. BMJ 2002;324:1088-1092.
35. Kolata G, Eichenwald K. Business thrives on unproven care, leaving science behind: A special report. New York Times October 3, 1999; A1, A40-41; See ref. 16, Mello and Breenan 2001, Welch 2002.
36. See ref. 16, Stadmauer et al. 2000; Lippman ME. High-dose chemotherapy plus autologous bone marrow transplantation for metastatic breast cancer. NEJM 2000;342:1119-1120;
37. Tallman MS, Gray R, Robert NJ, et al. Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancer. NEJM 2003;349:17-26.